Table 4.
Seroconversion rates based on Antigen-Specific Immunoglobulin Titers.
| Statistics | AZD1222 | MVC-COV1901 | Treatment Difference1, % | p-value2 |
|---|---|---|---|---|
| Seropositive in PPI Subset | ||||
| n | 71 | 73 | 0.5135 | |
| Seroconversion, n (%) | 64 (90.1) | 68 (93.2) | 3.0 | |
| 95 % CI | (83.2–97.1) | (87.4–98.9) | (-5.9–12.0) | |
| Seronegative in PPI Subset | ||||
| n | 38 | 43 | 1 | |
| Seroconversion, n (%) | 38 (100.0) | 43 (100.0) | 0 | |
| 95 % CI | (90.7–100.0) | (91.8–100.0) | (0.0–0.0) | |
Abbreviation: n = no. of participants, CI = confidence interval, GMT = geometric mean titer, GMFR = geometric mean fold rise, PPI = per-protocol immunogenicity.
Note: Seroconversion was defined as at least 4-fold increase of post-study intervention antibody titers from the baseline titer or from half of the lower limit of detection if undetectable at baseline.
[1] Treatment Difference was computed as, MVC-COV1901-AZD1222 and presented with the asymptotic 95 % CI. In the case of small cell count (expected count <5), exact 95 % CI was applied alternatively.
[2] P-value: Pearson's Chi-square test. In the case of small cell count (expected count <5), Fisher's exact test was applied alternatively.